Biosimilar Approval: How the FDA Reviews Biologic Alternatives in 2025
- Nov, 24 2025
- 0
The FDA's 2025 guidance streamlines biosimilar approval by reducing clinical trial requirements, cutting costs, and accelerating patient access to lower-cost biologic alternatives-while sparking debate over interchangeability and regulatory alignment.